Seeking Alpha

PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk

PDS Biotech is a clinical-stage company focused on developing immunotherapy-based approaches for cancer, with a focus on virus-driven tumors. Their main pipeline project is PDS0101, an immunotherapy ...
Seeking Alpha

PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results

PRINCETON, N.J., July 10, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune ...
Nasdaq

PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which ...

PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pipeline ...
Nasdaq

PDS Biotech Completes Enrollment of Lead-In Safety Cohort in VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer

FLORHAM PARK, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s ...